MX2009005503A - Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea. - Google Patents

Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.

Info

Publication number
MX2009005503A
MX2009005503A MX2009005503A MX2009005503A MX2009005503A MX 2009005503 A MX2009005503 A MX 2009005503A MX 2009005503 A MX2009005503 A MX 2009005503A MX 2009005503 A MX2009005503 A MX 2009005503A MX 2009005503 A MX2009005503 A MX 2009005503A
Authority
MX
Mexico
Prior art keywords
carnitine
medicament
drops
eye
preparation
Prior art date
Application number
MX2009005503A
Other languages
English (en)
Inventor
Aleardo Koverech
Nicola Pescosolido
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of MX2009005503A publication Critical patent/MX2009005503A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de L-carnitina o una sal farmacéuticamente aceptable de esta, para la preparación de un suplemento o medicamento fisiológico oftálmico en forma de gotas para los ojos, para el tratamiento de edema corneal.
MX2009005503A 2006-12-11 2007-11-21 Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea. MX2009005503A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06125770 2006-12-11
PCT/EP2007/062610 WO2008071524A1 (en) 2006-12-11 2007-11-21 Use of l-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases

Publications (1)

Publication Number Publication Date
MX2009005503A true MX2009005503A (es) 2009-06-04

Family

ID=37603705

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009005503A MX2009005503A (es) 2006-12-11 2007-11-21 Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.

Country Status (13)

Country Link
US (1) US8158679B2 (es)
EP (1) EP2091529A1 (es)
JP (1) JP5384362B2 (es)
KR (1) KR101447601B1 (es)
CN (1) CN101534812B (es)
AU (1) AU2007332680B2 (es)
BR (1) BRPI0720089A2 (es)
CA (1) CA2667069C (es)
EA (1) EA017752B1 (es)
HK (1) HK1135019A1 (es)
MX (1) MX2009005503A (es)
SG (1) SG176481A1 (es)
WO (1) WO2008071524A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101433152B1 (ko) * 2006-12-22 2014-08-22 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. 안과용 약물의 전달에 유용한 젤
TW201322982A (zh) * 2011-11-01 2013-06-16 Otsuka Pharma Co Ltd 用於治療前眼疾病之藥劑，該藥劑包含瑞巴派特及眼淚保持劑
EP2783695A1 (en) * 2013-03-28 2014-10-01 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin
FR3019465B1 (fr) 2014-04-02 2017-06-23 Horus Pharma Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08133968A (ja) * 1994-09-14 1996-05-28 Taisho Pharmaceut Co Ltd 角膜障害修復用点眼液
US6585987B1 (en) * 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
RU2165749C1 (ru) * 2000-07-06 2001-04-27 Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" Способ восстановления эндотелия роговицы
US7465463B2 (en) * 2002-09-04 2008-12-16 Polyheal, Ltd. Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues
US7820639B2 (en) * 2004-10-01 2010-10-26 Lindstrom Richard L Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
EP1906949B1 (en) * 2005-07-01 2015-02-11 SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye-drops

Also Published As

Publication number Publication date
CA2667069C (en) 2015-05-26
US20100068300A1 (en) 2010-03-18
KR101447601B1 (ko) 2014-10-07
AU2007332680B2 (en) 2013-02-07
WO2008071524A1 (en) 2008-06-19
CA2667069A1 (en) 2008-06-19
AU2007332680A1 (en) 2008-06-19
US8158679B2 (en) 2012-04-17
JP5384362B2 (ja) 2014-01-08
CN101534812A (zh) 2009-09-16
HK1135019A1 (en) 2010-05-28
KR20090087453A (ko) 2009-08-17
SG176481A1 (en) 2011-12-29
EP2091529A1 (en) 2009-08-26
BRPI0720089A2 (pt) 2013-12-24
EA017752B1 (ru) 2013-02-28
EA200970562A1 (ru) 2009-10-30
JP2010512363A (ja) 2010-04-22
CN101534812B (zh) 2012-09-05

Similar Documents

Publication Publication Date Title
TW200744574A (en) Use of L-carnitine or of alkanoyl L-carnitines for the preparation of a physiological supplement of medicament for ophthalmic use in the form of eye-drops
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
NZ589445A (en) Rasagiline for parkinson's disease modification
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
EA200802208A1 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
EP2371853A3 (en) Insulin derivatives or its pharmaceutically acceptable salt, pharmaceutical composition, use of insulin derivative or its pharmaceutically acceptable salt and method of treatment
WO2010068281A3 (en) Contact lens drug delivery device
WO2007035473A3 (en) Pharmaceutical delivery device and method for providing ocular treatment
MX2020008616A (es) Rocio de fentanilo sublingual.
WO2006017188A3 (en) Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
HK1098960A1 (en) Method and composition for treating rhinitis
TW200637544A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
RU2007122391A (ru) S-миртазапин для лечения приливов
WO2008045378A3 (en) Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
MY178169A (en) Topical ophthalmic peptide formulation
MX2009005503A (es) Uso de l-carnitina para la preparacion de un medicamento en forma de gotas oculares para el tratamiento de enfermedades de la cornea.
WO2008051527A3 (en) Sustained release of agents for localized pain management
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2007144889A3 (en) Treatment of neurofibromatosis
WO2007017652A3 (en) Arylakylamines for the treatment of cancer
MX2009011250A (es) Promotor de la formacion de neuritas.
UA27832U (en) Method for treating dystrophic and vascular diseases of retina and optic nerve

Legal Events

Date Code Title Description
FG Grant or registration